Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients

References

• Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, . Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339–54.
   PubMed Web of Science ®Google Scholar
• Katlama C, Esposito R, Gatell JM, Goffard JC, Grinsztejn B, Pozniak A, . Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007;21:395–402.
   PubMed Web of Science ®Google Scholar
• Haubrich R, Berger D, Chiliade P, Colson A, Conant M, Gallant J, . Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS 2007;21:F11–8.
   PubMed Web of Science ®Google Scholar
• Johnson M. Week-48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 591 treatment-experienced HIV-1 patients. Conference on Retroviruses and Opportunistic Infections (poster presentation). Boston, USA; 2008.
   Google Scholar
• Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, . Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359:1429–41.
   PubMed Web of Science ®Google Scholar
• Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, . Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007;46:125–33.
   PubMed Web of Science ®Google Scholar
• Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, . Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection (oral abstract session). N Engl J Med 2008;359:355–65.
   PubMed Web of Science ®Google Scholar
• Yazdanpanah Y. high rate of virologic success with raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced patients with multidrug-resistant virus: results of the ANRS 139 TRIO trial. XVII International AIDS Conference (oral abstract session). Mexico; 2008.
   Google Scholar
• Vray M, Meynard JL, Dalban C, Morand-Joubert L, Clavel F, Brun-Vezinet F, . Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088). Antivir Ther 2003;8:427–34.
   PubMed Web of Science ®Google Scholar
• Paredes R, Mocroft A, Kirk O, Lazzarin A, Barton SE, van Lunzen J, . Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med 2000;160:1123–32.
   PubMed Web of Science ®Google Scholar
• Paris D, Ledergerber B, Weber R, Jost J, Flepp M, Opravil M, . Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort. AIDS Res Hum Retroviruses 1999;15:1631–8.
   PubMed Web of Science ®Google Scholar
• Casado JL, Perez-Elias MJ, Antela A, Sabido R, Marti-Belda P, Dronda F, . Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients. AIDS 1998;12:F131–5.
   PubMed Web of Science ®Google Scholar
• Le Moing V, Chene G, Carrieri MP, Alioum A, Brun-Vezinet F, Piroth L, . Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS 2002;16:21–9.
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. USA guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington DC: Department of Health and Human Services; 2009. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL. Accessed date: December 1, 2009.
   Google Scholar
• Prise en charge médicale des personnes infectées par le VIH. Publisher: flammarion. Recommandations françaises du groupe d'experts sous la direction du Professeur P. YENI. August 22, 2008. Available at: http://www.sante.gouv.fr accessed date: august 19, 2008.
   Google Scholar
• European AIDS Clinical Society (EACS). Guidelines for the clinical management and treatment of HIV infected adults in Europe (2009). Available at: http://www.europeanaidsclinicalsociety.org. Accessed date: november 2009.
   Google Scholar
• Malet I, Delelis O, Valantin MA, Montes B, Soulie C, Wirden M, . Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 2008;52:1351–8.
   PubMed Web of Science ®Google Scholar
• Fikkert V, Hombrouck A, Van Remoortel B, De Maeyer M, Pannecouque C, De Clercq E, . Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360. AIDS 2004;18:2019–28.
   PubMed Web of Science ®Google Scholar
• Shafer RW, Schapiro JM. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev 2008;10:67–84.
   PubMed Web of Science ®Google Scholar
• Lataillade M, Chiarella J, Kozal MJ. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther 2007;12: 563–70.
   PubMed Web of Science ®Google Scholar
• Eron J. Switching from stable lopinavir/ritonavir (LPV/r)-based to raltegravir (RAL)-based combination antiretroviral therapy (ART) resulted in a superior lipid profile at week 12 but did not demonstrate non-inferior virologic efficacy at week 24. Conference on Retroviruses and Opportunistic Infections (oral abstract session). Montreal, Canada; 2009.
   Google Scholar
• Nijhuis M, van Maarseveen NM, Lastere S, Schipper P, Coakley E, Glass B, . A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med 2007;4:e36.
   PubMedGoogle Scholar